An interventional study of APP-based management in End Stage Renal Disease (ESRD) and Maintenance Hemodialysis, sponsored by Yunfeng Xia. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Yunfeng Xia · Not applicable, Interventional, and Health services research
Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.
Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.
Affected by their own diseases and various complications, many maintenance hemodialysis (MHD) patients have a negative and pessimistic attitude toward life. Their quality of life and prognosis have always been a concern for clinicians. Therefore, how to adjust and manage the lives of these patients, enable them to actively cooperate with various treatment methods, maximize the quality of blood purification therapy, and improve their quality of life and prognosis has become an extremely important research topic.
Exclusion Criteria:
For the APP management group, according to the specific conditions of patients such as age, gender, primary disease and complications, the "Yueya" mini-program and WeChat will be used to provide individualized and all-weather guidance for dialysis patients in their daily lives, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring and real-time feedback.
Behavioral: APP-based management
For the non-APP management group, the APP mini-program will not be used to guide patients' daily lives, and only the previous routine management methods will be adopted.
Based on patients' specific conditions such as age, gender, primary disease, and complications, the APP-based management will provide individualized and round-the-clock guidance for dialysis patients in their daily lives through the "Yueya" mini-program and WeChat. This guidance covers various aspects, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring, and real-time feedback.
mortality rate
In this study, mortality rate was used as a prognostic indicator.
Time frame: About 1 year
Hospitalization rate
In this study, the hospitalization rate was used as a prognostic indicator.
Time frame: About 1 year
Kidney Disease Quality of Life
Measuring the quality of life of hemodialysis patients through the Kidney Disease Quality of Life-36（KDQOL-36） scale. If the KDQOL-36 score increases, the quality of life is considered to be improved.
Time frame: About 1 year
Incidence of cardiovascular events
Time frame: About 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yunfeng Xia